C4 Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- C4 Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $176.00K.
- C4 Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $605.00K.
- C4 Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $107.00K, a 723.08% increase year-over-year.
- C4 Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $13.00K.
- C4 Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $107.00K, a 86.25% decline from fiscal 2024.
- C4 Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $778.00K, a 1241.38% increase from fiscal 2023.
- C4 Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $58.00K, a 92.54% decline from fiscal 2022.
- C4 Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $777.00K, a 66.65% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $176.00K 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $605.00K 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $107.00K 10-K · filed 2026-02-26 | |
| 2025-09-30 | $107.00K 10-Q · filed 2025-11-06 | |
| 2024-12-31 | $778.00K 10-K · filed 2026-02-26 | |
| 2024-09-30 | $13.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $135.00K 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $519.00K 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $58.00K 10-K · filed 2025-02-27 | |
| 2023-09-30 | $0.00 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $2.00K 10-Q · filed 2024-10-31 | |
| 2023-03-31 | $56.00K 10-Q · filed 2024-10-31 | |
| 2022-12-31 | $777.00K 10-K · filed 2024-02-22 | |
| 2022-09-30 | $211.00K 10-Q · filed 2023-11-01 | |
| 2022-06-30 | $259.00K 10-Q · filed 2023-11-01 | |
| 2022-03-31 | $260.00K 10-Q · filed 2023-11-01 | |
| 2021-12-31 | $2.33M 10-K · filed 2023-02-23 | |
| 2021-09-30 | $873.00K 10-Q · filed 2022-11-03 | $1.67M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $539.00K 10-Q · filed 2022-11-03 | $1.33M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-03-31 | $166.00K 10-Q · filed 2022-11-03 | $896.00K derived: sum of 4 quarters · filed 2022-11-03 |
| 2020-12-31 | $92.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $887.00K 10-K · filed 2022-02-24 |
| 2020-09-30 | $529.00K 10-Q · filed 2021-11-10 | $808.00K derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $109.00K 10-Q · filed 2021-11-10 | $492.00K derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $156.00K 10-Q · filed 2021-11-10 | |
| 2019-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $274.00K 10-K · filed 2022-02-24 |
| 2019-09-30 | $213.00K 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |